Home › Heart Diseases › NCT03204357

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

Targeted Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass: a Prospective Randomized Controlled Trial.

Who can join

Ages 18 to 90 · All sexes

Inclusion Criteria:

1. Adult subjects aged 18 to 90
2. Able to provide informed consent
3. Willing to accept autologous or allogenic blood transfusion
4. Scheduled for elective cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

1. Pre-operative administration of allogenic blood bank products in the previous 3 months
2. Hemodynamically unstable defined as a systolic blood pressure less than 90 mmHg with a heart rate greater 100 or requiring intravenous vasopressor medications
3. Significant active infection or sepsis defined by positive blood culture or positive wound culture
4. Hemoglobin less than 7 g/dl

About the study

Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels.

The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

What is being tested

• Fresh Autologous whole Blood (other)
• Standard of Care Expectant management of bleeding (other)

Sponsor: University of Colorado, Denver · Participants: 70 · Started: Jan 24, 2022

Contact the study team

• Nathan J Clendenen, M.D. · Phone: 720-848-6709
• Nick Naughton, B.A · Phone: 720-848-6709

Official record on ClinicalTrials.gov — NCT03204357

Locations in the U.S.

Conditions

• Heart Diseases
• Postoperative Hemorrhage

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.